EN · ES · CAT

The biotech company Aromics recieves 1 M€ from the European Union to boost its drug against the asbestos-related hallmark cancer

14/02/2019

The European Commission has allocated, through the H2020-EIC-SMEInst-2018-2020-Phase 2 program,  a total of 1,085.659€ to the BERMES project of Aromics, the objective of which is to complete the regulatory pre-clinical stage in order to begin studies in humans of the drug NAX035 for malignant mesothelioma, an aggressive and highly resistant cancer linked to asbestos exposur

+ info:

European Union